Cargando…

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus

The dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin is an oral, antidiabetic treatment that is approved in many countries to treat patients with type 2 diabetes mellitus (T2DM), including the USA, Europe, and Japan. Alogliptin is efficacious both as monotherapy and as add-on/combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, Kohei, Kisanuki, Koichi, Shibata, Mari, Oohira, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834733/ https://www.ncbi.nlm.nih.gov/pubmed/31654243 http://dx.doi.org/10.1007/s40264-019-00857-8

Ejemplares similares

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Randomized, double‐blind, phase III study to evaluate the efficacy and safety of once‐daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2017)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
por: Kim, Hae Jin, et al.
Publicado: (2022)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin
por: Wang, Hongyu, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2010)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes
por: Shigematsu, Erina, et al.
Publicado: (2017)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
por: Berhan, Asres, et al.
Publicado: (2013)

Treatment of Streptozotocin-Induced Diabetic Rats with Alogliptin: Effect on Vascular and Neural Complications
por: Davidson, Eric P., et al.
Publicado: (2011)

Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index
por: Aoki, Chie, et al.
Publicado: (2017)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
por: Mizushige, Tomoko, et al.
Publicado: (2015)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes
por: Nishimura, Rimei, et al.
Publicado: (2019)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
por: Liu, Xu, et al.
Publicado: (2021)

Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver
por: Yamamoto, Yutaro, et al.
Publicado: (2020)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Formulation and Optimization of Alogliptin-Loaded Polymeric Nanoparticles: In Vitro to In Vivo Assessment
por: Mohanty, Dibyalochan, et al.
Publicado: (2022)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
por: Kurozumi, Akira, et al.
Publicado: (2013)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Immunohistochemical Localization of Alogliptin, a DPP-4 Inhibitor, in Tissues of Normal and Type 2 Diabetes Model Rat
por: Yamamoto, Yutaro, et al.
Publicado: (2022)

Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial
por: Xu, Mingtong, et al.
Publicado: (2023)

Serious diabetic ketoacidosis induced by insulin allergy and anti‐insulin antibody in an individual with type 2 diabetes mellitus
por: Takahashi, Kaio, et al.
Publicado: (2022)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study
por: Mita, Tomoya, et al.
Publicado: (2023)

New prospects for incretin‐related drugs in the treatment of type 2 diabetes
por: Kimura, Tomohiko, et al.
Publicado: (2020)

Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits
por: Zhang, Xiaowei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uf5fivahpm6c97hc9ppfu1tsan